Is hVIVO still a top UK stock for growth after today’s full-year results? 

This UK stock has risen roughly 370% over the last five years. But Edward Sheldon believes it has the potential to keep rising.

| More on:
Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One UK stock I’ve been quite bullish on recently is hVIVO (LSE: HVO). It’s a small healthcare business that offers services for clinical trials and lab testing and serves four of the 10 largest biopharma companies worldwide.

This morning (9 April), the company – which is listed on the UK’s Alternative Investment Market (AIM) – posted its full-year results for 2023. Is it still a good stock to consider for growth? Let’s take a look.

2023 numbers

Today’s full-year results look pretty good, in my view.

For the year, revenue came in at £56m, up 16% year on year. Meanwhile, adjusted earnings per share (EPS) amounted to 1.27p, up 32%.

Encouragingly, the EBITDA (earnings before interest, tax, depreciation, and amortisation) margin was up significantly at 23.3% versus 18.7% for 2022.

It was also encouraging to see the company announce an annual dividend policy and start off with a payment of 0.2p per share.


Looking ahead, guidance was healthy.

For 2024, the group expects revenue of £62m with growth to be H1 weighted.

It added here that 90% of this 2024 revenue guidance is already contracted with good visibility into 2025 (it had a weighted contracted orderbook of £80m at the end of 2023).

Looking further out, the company is hoping to grow its revenues to £100m by 2028 through a combination of strong organic growth and small bolt-on acquisitions.

It noted that the group’s strong cash position (cash and cash equivalents of £37m at the end of 2023) underpins its M&A strategy.

The Company remains confident that 2024 will be another year of significant growth

hVIVO 2023 results

Plenty of potential

Looking at these numbers, I do still see hVIVO as a good stock for growth.

Clearly, the company plans to grow its top line significantly in the years ahead.

One thing that should help here is its upcoming move to a new state-of-the-art facility in Canary Wharf, London. This move will increase the group’s revenue potential (the facility will be the world’s largest commercial human challenge trial unit) and position the company for further profit margin improvements.

As for the valuation, it’s quite reasonable, in my view. If we take the 2023 EPS figure of 1.27p, the trailing price-to-earnings (P/E) ratio is only 22. That’s not so high, given the level of revenue and earnings growth the firm is generating.

It’s worth noting that last month, analysts at Peel Hunt initiated coverage of the stock with a ‘buy’ rating and a price target of 36p (nearly 30% above the current share price).

One other thing that’s worth mentioning here is the new dividend policy. The fact that the company has announced that it will start paying annual dividends suggests that management is very confident about the future.

Of course, there are risks to consider here. One is a dip in profits. As a small growth business (the market cap is just £200m), hVIVO doesn’t yet have a long-term track record of consistent profitability.

Another is competition. The firm has noted that some of its competitors have substantially greater resources than it does.

Overall though, I think the stock has a lot going for it. If I was looking to add to my UK growth stock holdings, I would definitely consider shares in hVIVO.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20,000 in savings? Here’s how I’d target a £2,219 monthly passive income with FTSE 100 shares

Investing in FTSE 100 shares can be a great way to turn a regular investment into a life-changing passive income…

Read more »

Investing Articles

These are the most popular 2024 Stocks and Shares ISA picks so far

After a few tough years, it looks like the 2024 Stocks and Shares ISA season is getting off to a…

Read more »

Investing Articles

This FTSE 100 ETF may be the simplest way to become a stock market millionaire

Ben McPoland considers one very straightforward stock market investing strategy that could lead to a million-pound portfolio.

Read more »

Investing Articles

I’d buy 11,220 Legal & General shares for £200 a month in passive income

Our writer considers how much money investors would have to put into Legal & General (LON:LGEN) shares to target £2,400…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

These 2 magnificent FTSE 250 shares are on sale right now!

These FTSE 250 companies still look cheap, despite recent share price gains. Here's why our writer Royston Wild thinks they’re…

Read more »

Blue NIO sports car in Oslo showroom
Growth Shares

Down 36% in 2024, how low could NIO shares go?

The electric vehicle sector has seen some tremendous volatility in recent years, but what does the future hold for NIO…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

£5,000 in savings? Here is how I would invest in income shares

This Fool has been searching for ways to generate a passive return via income shares.

Read more »

Market Movers

The Keywords Studios share price just jumped 63%. Time to sell?

The Keywords Studios share price has soared on the back of takeover talk. Here, Edward Sheldon explains what he’d do…

Read more »